- Public Comps
- SyntekaBio
SyntekaBio Valuation Multiples
Discover revenue and EBITDA valuation multiples for SyntekaBio and similar public comparables like TAO Synergies, Evaxion, VYNE Therapeutics, Advicenne and more.
SyntekaBio Overview
About SyntekaBio
SyntekaBio Inc is a bioinformatics venture firm. It is engaged in gene-related research, technology development, and genetic analysis based on the genome big data platform and artificial intelligence deep learning drug development platform. The company manages and analyzes genome analysis and massive biodata and genome.
Founded
2009
HQ

Employees
41
Website
Financials (FY)
EV
$22M
Valuation Multiples
Start free trialSyntekaBio Financials
SyntekaBio reported last fiscal year revenue of $2M and negative EBITDA of ($8M).
In the same fiscal year, SyntekaBio generated $2M in gross profit, ($8M) in EBITDA losses, and had net loss of ($12M).
Revenue (LTM)
SyntekaBio P&L
In the most recent fiscal year, SyntekaBio reported revenue of $2M and EBITDA of ($8M).
SyntekaBio is unprofitable as of last fiscal year, with gross margin of 100%, EBITDA margin of (365%), and net margin of (507%).
Financial data powered by Morningstar, Inc.
SyntekaBio Stock Performance
SyntekaBio has current market cap of $26M, and enterprise value of $22M.
Market Cap Evolution
SyntekaBio's stock price is $1.08.
SyntekaBio share price increased by 5.8% in the last 30 days, and decreased by 70.2% in the last year.
SyntekaBio has an EPS (earnings per share) of $-0.48.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $22M | $26M | 0.5% | 5.8% | -49.6% | -70.2% | $-0.48 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialSyntekaBio Valuation Multiples
SyntekaBio trades at 9.7x EV/Revenue multiple, and (2.6x) EV/EBITDA.
EV / Revenue (LTM)
SyntekaBio Financial Valuation Multiples
As of July 18, 2026, SyntekaBio has market cap of $26M and EV of $22M.
SyntekaBio has a P/E ratio of (2.2x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified SyntekaBio Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


SyntekaBio Margins & Growth Rates
In the most recent fiscal year, SyntekaBio reported gross margin of 100%, EBITDA margin of (365%), and net margin of (507%).
SyntekaBio Margins
SyntekaBio Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
SyntekaBio Operational KPIs
SyntekaBio's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.2M for the same period.
Data powered by FactSet, Inc. and Morningstar, Inc.
SyntekaBio Competitors
SyntekaBio competitors include TAO Synergies, Evaxion, VYNE Therapeutics, Advicenne, Oncocross, Atossa Therapeutics, BioXcel Therapeutics, NeuroSense Therapeutics, SoftOx Solutions and NextCure.
Most SyntekaBio public comparables operate across Biopharmaceuticals, BioTech and DeepTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 84.0x | - | (2.8x) | - | |||
| 1.3x | 1.6x | (1.4x) | - | |||
| (25.0x) | - | 0.5x | - | |||
| 6.8x | 6.5x | (12.2x) | (9.5x) | |||
| 58.0x | - | (2.8x) | - | |||
| - | - | 0.2x | - | |||
| 172.1x | 92.7x | (2.2x) | (2.4x) | |||
| - | - | (2.2x) | - | |||
This data is available for Pro users. Sign up to see all SyntekaBio competitors and their valuation data. Start Free Trial | ||||||
SyntekaBio VC Funding History
Before going public, SyntekaBio raised $33M in total equity funding, across 3 rounds.
SyntekaBio Funding Rounds
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout SyntekaBio
| When was SyntekaBio founded? | SyntekaBio was founded in 2009. |
| Where is SyntekaBio headquartered? | SyntekaBio is headquartered in South Korea. |
| How many employees does SyntekaBio have? | As of today, SyntekaBio has over 41 employees. |
| Is SyntekaBio publicly listed? | Yes, SyntekaBio is a public company listed on Korea Exchange. |
| What is the stock symbol of SyntekaBio? | SyntekaBio trades under 226330 ticker. |
| When did SyntekaBio go public? | SyntekaBio went public in 2019. |
| Who are competitors of SyntekaBio? | SyntekaBio main competitors include TAO Synergies, Evaxion, VYNE Therapeutics, Advicenne, Oncocross, Atossa Therapeutics, BioXcel Therapeutics, NeuroSense Therapeutics, SoftOx Solutions, NextCure. |
| What is the current market cap of SyntekaBio? | SyntekaBio's current market cap is $26M. |
| What is the current revenue of SyntekaBio? | SyntekaBio's last fiscal year revenue is $2M. |
| What is the current EV/Revenue multiple of SyntekaBio? | Current revenue multiple of SyntekaBio is 9.7x. |
| Is SyntekaBio profitable? | No, SyntekaBio is not profitable. |
| How many companies SyntekaBio has acquired to date? | SyntekaBio hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies SyntekaBio has invested to date? | SyntekaBio hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to SyntekaBio
Lists including SyntekaBio
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




